Accuracy of the New Injury Severity Score in Evaluating Patients With Blunt Trauma
Launched by AL-NAHRAIN UNIVERSITY · Nov 28, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new scoring system called the New Injury Severity Score (NISS) to see how well it can predict outcomes, like survival rates, for patients who have experienced blunt trauma, such as injuries from car accidents or falls. The researchers are specifically looking at whether this score can accurately indicate which patients might need intensive care or how long they might stay in the hospital.
To participate in this trial, patients must be 18 years or older and be admitted to the emergency department with blunt trauma. They need to have clear medical records that show their injuries and vital signs so that the NISS can be calculated accurately. Once enrolled, participants will have their NISS score calculated shortly after they arrive at the hospital, and their health outcomes will be monitored throughout their hospital stay. It's important to note that patients with certain medical conditions, those under 18, or those who are unable to provide consent will not be eligible for this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Trauma patients admitted to the emergency department, presenting with blunt trauma, such as from motor vehicle accidents, falls, or assaults.
- • Patients with adequate documentation of anatomical injuries and physiological parameters required for NISS calculation.
- • Injury assessment and NISS calculation completed within the first 6 hours of arrival to ensure accuracy and consistency in trauma evaluation.
- Exclusion Criteria:
- • Patients under 18 years, pregnant women, or those with pre-existing medical conditions that may alter trauma scoring accuracy or management outcomes.
- • Patients presenting with medical emergencies, terminal illnesses, or conditions unrelated to blunt trauma to ensure focus on trauma-specific evaluations.
- • Patients declared dead on arrival or who do not receive active treatment in the emergency department.
- • Patients or their families refusing participation or withdrawing consent at any stage of the study.
- • Patients transferred from or to another facility or those previously treated elsewhere, as this may affect data collection and scoring reliability.
About Al Nahrain University
Al-Nahrain University is a leading academic institution dedicated to advancing medical research and education in Iraq. With a focus on innovative clinical trials, the university aims to enhance healthcare outcomes through rigorous scientific investigation and collaboration with local and international partners. Its commitment to ethical research practices and adherence to regulatory standards positions Al-Nahrain University as a pivotal contributor to the development of new therapeutic interventions and the overall improvement of public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baghdad, , Iraq
Patients applied
Trial Officials
Rawa'a A. Sattar A. Wahhab, MBBCH FICS CABMS FACS
Study Director
College Of Medicine - Nahrain University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported